B1 Non-refereed article in a scientific journal

Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues




AuthorsKatherine A Rauen, Susan M Huson, Emma Burkitt-Wright, D Gareth Evans, Said Farschtschi, Rosalie E Ferner, David H Gutmann, C Oliver Hanemann, Bronwyn Kerr, Eric Legius, Luis F Parada, Michael Patton, Juha Peltonen, Nancy Ratner, Vincent M Riccardi, Thijs van der Vaart, Miikka Vikkula, David H Viskochil, Martin Zenker, Meena Upadhyaya

Publication year2015

JournalAmerican Journal of Medical Genetics Part A

Volume167

Issue1

First page 1

Last page10

Number of pages10

ISSN1552-4825

DOIhttps://doi.org/10.1002/ajmg.a.36793


Abstract

Neurofibromatosis type 1 (NF1) was the first RASopathy and is now one of many RASopathies that are caused by germline mutations in genes that encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Their common underlying pathogenetic etiology causes significant overlap in phenotypic features which includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, GI and ocular abnormalities, and a predisposition to cancer. The proceedings from the symposium “Recent Developments in Neurofibromatoses (NF) and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues” chronicle this timely and topical clinical translational research symposium. The overarching goal was to bring together clinicians, basic scientists, physician-scientists, advocate leaders, trainees, students and individuals with Ras pathway syndromes to discuss the most state-of-the-art basic science and clinical issues in an effort to spark collaborations directed towards the best practices and therapies for individuals with RASopathies. © 2014 Wiley Periodicals, Inc.



Last updated on 2024-26-11 at 17:06